ALK and neoplasm: Moreover, mean tumor-specific survival was significantly shorter in the ALK IHC-positive group than in the ALK IHC-negative group (47.8 months vs 58.1 months, respectively; P = 0.026), and the 2-year tumor-specific survival rate of ALK IHC-positive patients was lower than that of ALK IHC-negative patients (82.7% vs 91.3%, respectively; P = 0.092).